TROV - TrovaGene, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.2526
-0.1778 (-41.3104%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.4304
Open0.2500
Bid0.2500 x 4000
Ask0.2890 x 4000
Day's Range0.2375 - 0.2650
52 Week Range0.2375 - 2.8500
Volume12,989,663
Avg. Volume660,973
Market Cap9.626M
Beta-0.53
PE Ratio (TTM)N/A
EPS (TTM)-1.0120
Earnings DateMar 13, 2018 - Mar 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • SmarterAnalyst2 days ago

    Why TrovaGene Inc (TROV) Stock Tanked 40% Today

    Each share of common stock is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.30 per share and accompanying common warrant. The common warrants will be exercisable immediately at an exercise price of $0.30 per share and will expire five years from the date of issuance. Added to its current 38.11 million shares outstanding, this offering promises to dilute existing shareholders by at least 40% -- coincidentally, about the same amount that the stock is down today. Another reason investors may be selling off TrovaGene stock is the price at which these new shares are being offered.

  • Trovagene Prices $4.5 Million Public Offering
    PR Newswire2 days ago

    Trovagene Prices $4.5 Million Public Offering

    SAN DIEGO, Dec. 15, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the pricing of a public offering of 15,000,000 shares of its common stock (or common stock equivalents) and common warrants to purchase up to an aggregate of 15,000,000 shares of common stock. Each share of common stock (or common stock equivalent) is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.30 per share and accompanying common warrant.

  • Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer
    PR Newswire3 days ago

    Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer

    SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, engaged in the development of targeted cancer therapies, today announced the filing of its protocol for a Phase 2 clinical trial of PCM-075 in combination with abiraterone acetate (Zytiga® - Johnson & Johnson), for metastatic Castration-Resistant Prostate Cancer (mCRPC) has been submitted to the U.S. Food and Drug Administration (FDA) for review. In this multi-center, open-label, Phase 2 trial, PCM-075 in combination with the standard dose of abiraterone and prednisone, all administered orally, will be evaluated for safety and efficacy.

  • Trovagene Announces the Launch of NextCollect™ Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers
    PR Newswire5 days ago

    Trovagene Announces the Launch of NextCollect™ Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers

    SAN DIEGO, Dec. 12, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its proprietary NextCollect™ urine collection and DNA preservation kit is now available, for research use only, to clinical research laboratories and pharmaceutical customers.  NextCollect™ is being offered to both existing contracted clients and to new customers through an online ordering web distribution portal. NextCollect™ enables high-volume, non-invasive urine sample collection and isolation of DNA, and has the potential to expand the utility of nucleic acid testing from urine, including oncology, virology and infectious disease.

  • Capital Cube6 days ago

    ETFs with exposure to TrovaGene, Inc. : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TrovaGene, Inc. Here are 5 ETFs with the largest exposure to TROV-US. Comparing the performance and risk of TrovaGene, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)
    PR Newswire9 days ago

    Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)

    Targeted treatment with highly selective Polo-like Kinase 1 inhibitor, PCM-075, may represent a new option in TNBC, particularly in combination with other abiraterone acetate SAN DIEGO , Dec. 7, 2017 /PRNewswire/ ...

  • Interested In TrovaGene Inc (TROV)? Here’s What Its Recent Track-Record Looks Like
    Simply Wall St.10 days ago

    Interested In TrovaGene Inc (TROV)? Here’s What Its Recent Track-Record Looks Like

    Investors with a long-term horizong may find it valuable to assess TrovaGene Inc’s (NASDAQ:TROV) earnings trend over time and against its industry benchmark as opposed to simply looking at aRead More...

  • Capital Cube17 days ago

    ETFs with exposure to TrovaGene, Inc. : November 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TrovaGene, Inc. Here are 5 ETFs with the largest exposure to TROV-US. Comparing the performance and risk of TrovaGene, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • TrovaGene, Inc. :TROV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube18 days ago

    TrovaGene, Inc. :TROV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis TrovaGene, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of TrovaGene, Inc. – Genomic Health, Inc., Biocept, Inc., Laboratory Corporation of America Holdings, Exact Sciences Corporation, Quest Diagnostics Incorporated, PerkinElmer, Inc. and QIAGEN NV (GHDX-US, BIOC-US, LH-US, EXAS-US, DGX-US, ... Read more (Read more...)

  • What does TrovaGene Inc’s (TROV) Balance Sheet Tell Us Abouts Its Future?
    Simply Wall St.27 days ago

    What does TrovaGene Inc’s (TROV) Balance Sheet Tell Us Abouts Its Future?

    While small-cap stocks, such as TrovaGene Inc (NASDAQ:TROV) with its market cap of USD $24.01M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075
    PR Newswirelast month

    Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075

    SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the activation of its clinical trial site for its Phase 1b/2 multicenter trial of PCM-075 in patients with AML, with Virginia Cancer Specialists and Principal Investigator, Dr. Alexander Spira. This trial will enroll subjects in the Phase 1b who have relapsed or have resistant disease to no more than three prior regimens. The Phase 1b is a dose escalation study to determine a recommend phase 2 dose.  The Phase 2 continuation study will provide preliminary evaluation of anti-leukemic activity and will enroll newly diagnosed subjects, judged to be ineligible for, or who have refused, standard intensive induction therapy, as well as subjects who have relapsed after treatment with no more than one prior regimen.

  • Associated Presslast month

    Trovagene reports 3Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 12 cents. The molecular diagnostic company posted revenue of $123,000 in the period. The company's shares closed at 68 cents. A year ...

  • Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results
    PR Newswirelast month

    Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results

    SAN DIEGO , Nov. 9, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, today announced company highlights and financial results for the third ...

  • Capital Cube2 months ago

    ETFs with exposure to TrovaGene, Inc. : November 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TrovaGene, Inc. Here are 5 ETFs with the largest exposure to TROV-US. Comparing the performance and risk of TrovaGene, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)
    PR Newswire2 months ago

    FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)

    SAN DIEGO, Oct. 9, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) granted an orphan drug designation to PCM-075 for the treatment of patients with acute myeloid leukemia (AML) on September 28, 2017. PCM-075 is an oral, highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine Polo-like Kinase 1 (PLK1) enzyme, which appears to be over expressed in several different hematologic malignancies and solid tumor cancers.

  • When Will TrovaGene Inc (TROV) Run Out Of Cash?
    Simply Wall St.2 months ago

    When Will TrovaGene Inc (TROV) Run Out Of Cash?

    TrovaGene Inc (NASDAQ:TROV) announced a loss of -$36.81M in its most recent earnings update. Although some investors expected this, their belief in the path to profitability for TROV may beRead More...

  • Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis
    PR Newswire3 months ago

    Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis

    SAN DIEGO, Sept. 20, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the expansion and strengthening of its Board of Directors with the appointment of Athena Countouriotis, M.D. Dr. Countouriotis brings significant experience leading clinical development programs, from preclinical through clinical stages, and approval.  Over the course of her career, she has been involved in multiple clinical programs, with a focus within oncology, both hematologic and solid tumor indications, that have supported regulatory approvals in the U.S. and Europe.  Dr. Countouriotis currently serves as Senior Vice President, Chief Medical Officer at Adverum Biotechnologies.

  • What Does TrovaGene Inc’s (TROV) Share Price Indicate?
    Simply Wall St.3 months ago

    What Does TrovaGene Inc’s (TROV) Share Price Indicate?

    TrovaGene Inc (NASDAQ:TROV), a pharmaceuticals, biotechnology and life sciences company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the overRead More...

  • Capital Cube4 months ago

    ETFs with exposure to TrovaGene, Inc. : September 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TrovaGene, Inc. Here are 5 ETFs with the largest exposure to TROV-US. Comparing the performance and risk of TrovaGene, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Trovagene Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
    PR Newswire4 months ago

    Trovagene Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017

    SAN DIEGO, Aug. 31, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

  • PR Newswire4 months ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Trovagene, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Aug. 30, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • TrovaGene, Inc. :TROV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube4 months ago

    TrovaGene, Inc. :TROV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis TrovaGene, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of TrovaGene, Inc. – Genomic Health, Inc., Biocept, Inc., Laboratory Corporation of America Holdings, Exact Sciences Corporation, Quest Diagnostics Incorporated, PerkinElmer, Inc. and QIAGEN NV (GHDX-US, BIOC-US, LH-US, EXAS-US, DGX-US, ... Read more (Read more...)

  • Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines
    PR Newswire4 months ago

    Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines

    Additionally, Trovagene announces PCM-075 synergy in combination with more than ten chemo and targeted therapeutics across a broad range of solid tumor and hematologic malignancies SAN DIEGO , Aug. 21, ...

  • Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy
    PR Newswire4 months ago

    Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy

    SAN DIEGO, Aug. 16, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced positive data from a preclinical in-vivo study examining the combination of their PLK1 inhibitor, PCM-075, with a leading investigational FLT3 Inhibitor.  This FLT3 mutant xenograft model shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition versus monotherapy with Quizartinib (81%) or PCM-075 (76%).  This research data is planned for future publication. "Thirty percent of patients with AML harbor a FLT3 mutation.

  • Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results
    PR Newswire4 months ago

    Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results

    SAN DIEGO , Aug. 9, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced company highlights and financial results for the second quarter ended ...